Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salmeterol + fluticasone is a combination medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for the relief of acute symptoms or attacks. The combination contains two active ingredients: fluticasone propionate (an inhaled corticosteroid) and salmeterol xinafoate (a long-acting beta-agonist). Fluticasone reduces inflammation in the airways by inhibiting inflammatory mediators, while salmeterol relaxes bronchial smooth muscle by stimulating beta-2 adrenergic receptors, leading to bronchodilation. This dual mechanism helps prevent asthma attacks and COPD exacerbations when used regularly as prescribed[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salmeterol + fluticasone (GSK).